More than 30 companies to produce generic version of Pfizer's COVID pill

  • 📰 ABC
  • ⏱ Reading Time:
  • 30 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 51%

مصر أخبار أخبار

مصر أحدث الأخبار,مصر عناوين

The United Nations-backed Medicines Patent Pool announced Thursday it has signed an agreement with 35 companies around the globe to produce generic versions of Pfizer's COVID-19 antiviral pill.

The statement continued:"The MPP sublicensees and the additional capacity for COVID-19 treatment they will supply will play a critical role to help ensure that people everywhere, particularly those living in the poorest parts of the world, have equitable access to an oral treatment option against COVID-19."

Together, they prevent an enzyme the virus uses to make copies of itself inside human cells and spread throughout the body. The companies producing the drug span 12 countries including Bangladesh, Brazil, China, the Dominican Republic, Jordan, India, Israel, Mexico, Pakistan, Serbia, South Korea and Vietnam.

Under the agreement, the 35 companies will not be required to pay Pfizer royalties as long as COVID-19 is classified as a public health emergency by the World Health Organization.Paxlovid antiviral medication in a warehouse in Shoham, Israel, Jan. 18, 2022.

 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.

Its all about the money, always has been from the beginning. Over the counter cold and flu meds work wonders.

Ivermectin 2.0

😲

Little late in the game

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 471. in EG

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Pfizer COVID antiviral: Dozens of companies to start making pillNearly three dozen companies in Asia, the Caribbean, the Middle East and Eastern Europe will soon start making either generic versions of Pfizer's coronavirus pill or the raw ingredients. This deal will make the antiviral nirmatrelvir, or Paxlovoid, available to more than half of the world's population.
مصدر: fox13seattle - 🏆 328. / 59 اقرأ أكثر »